Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease

New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.

≈